Clinical Trials
13 trialsNCT07597941 2026-06-04
Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
The Affiliated People's Hospital of Ningbo University
Phase 2/3 Not yet recruiting
NCT02390752 2026-06-01
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT02688140 2026-05-29
TUD-APOLLO-064
Technische Universität Dresden
Phase 3 Completed
NCT03253848 2026-05-29
Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia
Eastern Cooperative Oncology Group
Phase NA Active not recruiting
NCT01409161 2026-05-20
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT02390635 2026-04-17
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT07504458 2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3 Recruiting
NCT07296445 2025-12-29
LATITUDE
SDK Therapeutics, Inc.
Phase 3 Not yet recruiting
NCT02938858 2025-12-11
French Registry of First-line Treatment of Acute Promyelocytic Leukemia
Groupe Francophone des Myelodysplasies
Active not recruiting
NCT06882031 2025-11-18
Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
SDK Therapeutics, Inc.
Phase 1 Completed
NCT07203885 2025-10-31
LEAP
Harvard Medical School (HMS and HSDM)
Phase NA Completed
NCT07187505 2025-09-23
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
Anhui Medical University
Phase NA Active not recruiting
NCT04687176 2025-06-12
Frontline Oral Arsenic Trioxide for APL
The University of Hong Kong
Phase 2 Recruiting